These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25109842)

  • 1. Analysis of vigabatrin treatment causing visual field defects in infantile spasms.
    Chiron C; Dulac O
    Dev Med Child Neurol; 2015 Jan; 57(1):9-10. PubMed ID: 25109842
    [No Abstract]   [Full Text] [Related]  

  • 2. Infantile spasms and vigabatrin. Visual field defects may be permanent.
    Lhatoo SD; Sander JW
    BMJ; 1999 Jan; 318(7175):57. PubMed ID: 10068225
    [No Abstract]   [Full Text] [Related]  

  • 3. Measuring field loss in children administered vigabatrin: a problem in search of a solution.
    Good WV
    J AAPOS; 2011 Oct; 15(5):411-2. PubMed ID: 22108349
    [No Abstract]   [Full Text] [Related]  

  • 4. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
    Riikonen R; Rener-Primec Z; Carmant L; Dorofeeva M; Hollody K; Szabo I; Krajnc BS; Wohlrab G; Sorri I
    Dev Med Child Neurol; 2015 Jan; 57(1):60-7. PubMed ID: 25145415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vigabatrin: an antiepileptic drug with major benefits but significant adverse effects.
    Besag FM
    Curr Drug Saf; 2010 Jul; 5(3):188-90. PubMed ID: 20624131
    [No Abstract]   [Full Text] [Related]  

  • 6. Vigabatrin therapy in infantile spasms: solving one problem and inducing another?
    Wohlrab G; Leiba H; Kästle R; Ramelli G; Schmitt-Mechelke T; Schmitt B; Landau K
    Epilepsia; 2009 Aug; 50(8):2006-8. PubMed ID: 19682036
    [No Abstract]   [Full Text] [Related]  

  • 7. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
    Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
    Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?
    Riikonen R
    Epilepsia; 2009 Aug; 50(8):2005-6. PubMed ID: 19682035
    [No Abstract]   [Full Text] [Related]  

  • 11. [Vigabatrin and visual fields defects].
    Jensen K
    Ugeskr Laeger; 2001 Jan; 163(2):184. PubMed ID: 11379251
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Constriction of the visual field by vigabatrin].
    Asensio Sánchez VM
    An Med Interna; 2002 Dec; 19(12):655-6. PubMed ID: 12593042
    [No Abstract]   [Full Text] [Related]  

  • 16. Are vigabatrin-associated visual field constrictions asymptomatic?
    Schmidt T; Rüther K; Schmitz B
    J Neurol; 2004 Jul; 251(7):887-8. PubMed ID: 15258797
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.
    Durbin S; Mirabella G; Buncic JR; Westall CA
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):4011-6. PubMed ID: 19279311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of treatments for infantile spasms.
    Nabbout R
    Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
    Kumar N; Jivan S
    Eye (Lond); 2006 Sep; 20(9):1082-3; author reply 1083-4. PubMed ID: 16244645
    [No Abstract]   [Full Text] [Related]  

  • 20. Vigabatrin-associated visual field loss.
    Fecarotta C; Sergott RC
    Int Ophthalmol Clin; 2012; 52(3):87-94, xii. PubMed ID: 22668542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.